Administration route |
intraprostatic injection |
Dosage |
1E10~1E12 vp |
Pts |
15 |
Age |
Adult, Older_Adult |
Outcome |
Increase in IL-12, IFNγ, and CXCL10 was observed in 57%, 93%, and 79% patients, respectively. The PSA doubling time (PSADT) pre and post treatment has a median of 1.55 years vs 1.18 years. |
Adverse reactions |
Chills; Mental status change; Dehydration; Diarrhea; Dyspnea; Fatigue; Fever; Flu-like symptoms; Nausea; Urinary frequency; Vomiting; Malaise; Pain(thigh, kidney, head, fingers); Anemia; Leukopenia; Lymphopenia; Neutropenia; Thrombocytopenia |
References |
PMID:
37713401
|
|